Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03089099
Recruitment Status : Unknown
Verified April 2017 by Bo Dai, Fudan University. Recruitment status was: Recruiting
As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed. Considered a "liquid biopsy," these circulating tumor cells (CTCs) can show how a patient's cancer responded to treatments. The purpose of this study is to determine whether sequentially analyzing the expression of molecular markers in high volume circulating tumor cells in metastatic castration-resistant prostate cancer patients can predict the therapeutic effects and outcomes of these patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with newly Diagnosed High Volume Metastatic Castration-Resistant Prostate Cancer.
18 yrs and older, and 80 yrs and younger
Histologically or cytologically proven prostate adenocarcinoma;
Imaging examinations including Emission Computed Tomography (ECT), Positron Emission Tomography (PET) and so on revealed a high-volume disease of patients(A high-volume of disease was defined by the presence of visceral metastases or four or more bone lesions with at least one beyond the vertebral bodies and pelvis)
Have been received hormonal therapy and progressed into castration-resistant stage
Not yet receiving chemotherapy
Patients are willing to participate and can be followed up regularly
Received the treatment of abiraterone acetate previously
Patients received chemotherapy previously
Combined with other malignant tumor history (in addition to the skin basal cell carcinoma or other tumors that have been cured more than five years).